The European Medicines Agency (EMA) expanded today the recommendation from vaccine of Modern, currently authorized in the European Union in greater old, for teenagers from between 12 and 17 years old.
The agency established for this group of population the same indications that are established for those over 18 years of age, that is, administer the vaccine in two doses, with a intervalo de four weeks and in the upper arm.
The study carried out by the EMA pTo recommend the inoculation of Moderna in adolescents involved 3,732 people between 12 and 17 yearsyes, of whichs 2,163 received the vaccine.
Of that group, no young developed the covid-19 and its members they developed an answer from antibodies comparable “To the one observed in Adults young of 18 to 25 years old “the agency said in a statement.
ALSO READ: Mother dies in China after saving her baby in landslide (Video)
In the group of control, formed by 1,073 children who received a injection of placebor, four of them are they infected of covid-19.
These results led to EMA to conclude that the effectiveness of Spikevax -commercial name of Moderna vaccine- in adolescents aged 12 to 17 years “is similarr” a la registered in adults.
The side effects most common in this group of population are the themselves what in adults: pain and swelling in the place of the injection, feeling tired, pain head, pain muscular Y articular, enlargement of lymph nodes, chills, sickness, vomiting and fever, which “are usually light to moderate and they improve within days of vaccination, ”the agency said.
The EMA recognized that It is probable what have not been detected new side effects in people between 12 and 17 years old “debido al limited number of children and adolescents included in the study”.
However, he assured that the benefits of Moderna’s vaccine for this population group “outweigh the risks, particularly in those with conditions that increase the risk of severe COVID-19.”